Track topics on Twitter Track topics that are important to you
Published on BioPortfolio: 2014-10-22T21:49:46-0400
This study will evaluate the relative bioavailability of 2 oral formulations of TKI258, and the effect of food on the bioavailability of TKI258, in adult patients with advanced solid tumor
This study will evaluate the efficacy of TKI258 in patients with advanced urothelial cancer
This study is an open-label, dose-escalating study to delineate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of TKI258. Pharmacokinetics and pharmacodynamics will be perfo...
The purpose of this phase II study of TKI258 (Dovitinib) in adenoid cystic carcinoma is to evaluate the efficacy of TKI258 (Dovitinib).
This study will evaluate safety and efficacy of TKI258 in patients with relapsed or refractory multiple myeloma
The Milan System for Reporting Salivary Gland Cytopathology is a tiered classification scheme that includes 6 diagnostic categories. Neoplasm, which is 1 of the 6 proposed categories, consists of beni...
Blastic plasmacytoid dendritic cell neoplasm is an aggressive neoplasm with a median survival of only a few months despite treatment. An exhaustive immunohistochemical workup is required to differenti...
Biliary mucinous cystic neoplasms are rare parenchymal neoplasms with a considerable malignant potential. Due to a lack of diagnostic imaging criteria, histopathologic evaluation remains the definitiv...
The classification of mucinous neoplasm of the appendix is controversial. Although they lack overtly malignant features, they can be complicated by extra-appendiceal spread leading to pseudomyxoma per...
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive neoplasm with leukemic features and frequent skin involvement. Translocations involving the MYC locus have been recently identifie...
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Disappearance of a neoplasm or neoplastic state without the intervention of therapy.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.